178 related articles for article (PubMed ID: 23394523)
1. New insights in mast cell modulation by palmitoylethanolamide.
De Filippis D; Negro L; Vaia M; Cinelli MP; Iuvone T
CNS Neurol Disord Drug Targets; 2013 Feb; 12(1):78-83. PubMed ID: 23394523
[TBL] [Abstract][Full Text] [Related]
2. Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide.
Bettoni I; Comelli F; Colombo A; Bonfanti P; Costa B
CNS Neurol Disord Drug Targets; 2013 Feb; 12(1):34-44. PubMed ID: 23394519
[TBL] [Abstract][Full Text] [Related]
3. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation.
Mazzari S; Canella R; Petrelli L; Marcolongo G; Leon A
Eur J Pharmacol; 1996 Apr; 300(3):227-36. PubMed ID: 8739213
[TBL] [Abstract][Full Text] [Related]
4. Palmitoylethanolamide regulates development of intestinal radiation injury in a mast cell-dependent manner.
Wang J; Zheng J; Kulkarni A; Wang W; Garg S; Prather PL; Hauer-Jensen M
Dig Dis Sci; 2014 Nov; 59(11):2693-703. PubMed ID: 24848354
[TBL] [Abstract][Full Text] [Related]
5. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.
Skaper SD; Facci L; Fusco M; Della Valle MF; Zusso M; Costa B; Giusti P
Inflammopharmacology; 2014 Apr; 22(2):79-94. PubMed ID: 24178954
[TBL] [Abstract][Full Text] [Related]
6. Ultramicronized Palmitoylethanolamide and Paracetamol, a New Association to Relieve Hyperalgesia and Pain in a Sciatic Nerve Injury Model in Rat.
Peritore AF; Siracusa R; Fusco R; Gugliandolo E; D'Amico R; Cordaro M; Crupi R; Genovese T; Impellizzeri D; Cuzzocrea S; Di Paola R
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429243
[TBL] [Abstract][Full Text] [Related]
7. Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide.
Skaper SD; Facci L
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3312-25. PubMed ID: 23108549
[TBL] [Abstract][Full Text] [Related]
8. Palmitoylethanolamide inhibits rMCP-5 expression by regulating MITF activation in rat chronic granulomatous inflammation.
De Filippis D; Russo A; De Stefano D; Cipriano M; Esposito D; Grassia G; Carnuccio R; Russo G; Iuvone T
Eur J Pharmacol; 2014 Feb; 725():64-9. PubMed ID: 24440533
[TBL] [Abstract][Full Text] [Related]
9. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma.
Esposito E; Cuzzocrea S
Mini Rev Med Chem; 2013 Feb; 13(2):237-55. PubMed ID: 22697514
[TBL] [Abstract][Full Text] [Related]
10. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors.
Costa B; Comelli F; Bettoni I; Colleoni M; Giagnoni G
Pain; 2008 Oct; 139(3):541-550. PubMed ID: 18602217
[TBL] [Abstract][Full Text] [Related]
11. Ultramicronized palmitoylethanolamide reduces viscerovisceral hyperalgesia in a rat model of endometriosis plus ureteral calculosis: role of mast cells.
Iuvone T; Affaitati G; De Filippis D; Lopopolo M; Grassia G; Lapenna D; Negro L; Costantini R; Vaia M; Cipollone F; Ialenti A; Giamberardino MA
Pain; 2016 Jan; 157(1):80-91. PubMed ID: 25974242
[TBL] [Abstract][Full Text] [Related]
12. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells.
Cerrato S; Brazis P; della Valle MF; Miolo A; Puigdemont A
Vet Immunol Immunopathol; 2010 Jan; 133(1):9-15. PubMed ID: 19625089
[TBL] [Abstract][Full Text] [Related]
13. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator.
Skaper SD; Facci L; Giusti P
Mol Neurobiol; 2013 Oct; 48(2):340-52. PubMed ID: 23813098
[TBL] [Abstract][Full Text] [Related]
14. Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats.
De Filippis D; Luongo L; Cipriano M; Palazzo E; Cinelli MP; de Novellis V; Maione S; Iuvone T
Mol Pain; 2011 Jan; 7():3. PubMed ID: 21219627
[TBL] [Abstract][Full Text] [Related]
15. Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain.
Ardizzone A; Fusco R; Casili G; Lanza M; Impellizzeri D; Esposito E; Cuzzocrea S
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671213
[TBL] [Abstract][Full Text] [Related]
16. N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution.
Skaper SD; Facci L; Barbierato M; Zusso M; Bruschetta G; Impellizzeri D; Cuzzocrea S; Giusti P
Mol Neurobiol; 2015 Oct; 52(2):1034-42. PubMed ID: 26055231
[TBL] [Abstract][Full Text] [Related]
17. Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis.
Vaia M; Petrosino S; De Filippis D; Negro L; Guarino A; Carnuccio R; Di Marzo V; Iuvone T
Eur J Pharmacol; 2016 Nov; 791():669-674. PubMed ID: 27720681
[TBL] [Abstract][Full Text] [Related]
18. Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis.
Abramo F; Campora L; Albanese F; della Valle MF; Cristino L; Petrosino S; Di Marzo V; Miragliotta V
BMC Vet Res; 2014 Jan; 10():21. PubMed ID: 24423192
[TBL] [Abstract][Full Text] [Related]
19. Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation.
De Filippis D; D'Amico A; Iuvone T
J Neuroendocrinol; 2008 May; 20 Suppl 1():20-5. PubMed ID: 18426495
[TBL] [Abstract][Full Text] [Related]
20. Reply to: "Palmitoylethanolamide: problems regarding micronization, ultra-micronization and additives" Inflammopharmacology DOI:10.1007/s10787-014-0202-3.
Skaper SD; Facci L; Fusco M; Della Valle MF; Zusso M; Costa B; Giusti P
Inflammopharmacology; 2015 Jun; 23(2-3):127-30. PubMed ID: 24862356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
